Abstract: Peptides and conjugates are described herein, including peptides having antimicrobial and/or anticancer properties, as are compositions, articles, and kits comprising such peptides and conjugates, and methods for using the peptides and conjugates.
Type:
Grant
Filed:
December 11, 2019
Date of Patent:
September 20, 2022
Assignee:
GEORGE MASON RESEARCH FOUNDATION, INC.
Inventors:
Barney Bishop, Saswata K. Sahoo, Justin Davis
Abstract: The present application provides a cell penetrating peptide consisting of the amino acid sequence of SEQ ID NO: 1, a cell penetrating peptide consisting of the amino acid sequence of SEQ ID NO: 2 and a cell penetrating peptide consisting of the amino acid sequence of SEQ ID NO: 3; and a complex comprising any one of the cell penetrating peptide and a functional molecule.
Type:
Grant
Filed:
December 10, 2018
Date of Patent:
August 16, 2022
Assignees:
Astellas Pharma Inc., National Center for Global Health and Medicine, Hiroshima University
Abstract: The present invention relates to an isolated peptide, an anti-cancer medicinal composition including the same and a method of specifically reducing or inhibiting activities of cancer cells using the same. The isolated peptide including a TAT basic domain conjugated to a GABARAPL2 H2 domain can specifically reduce or inhibit an activity of cancer cells, thereby being applied to the anti-cancer medicinal composition and the method of specifically reducing or inhibiting activities of cancer cells using the same.
Abstract: Novel collagen mimics are disclosed with a tripeptide unit having the formula (Xaa-Yaa-Gly)n, where one of the positions Xaa or Yaa is a bulky, non-electron withdrawing proline derivative. By substituting a proline derivative at either the Xaa or Yaa position in the native collagen helix, the stability of the helix is increased due solely to steric effects relative to prior known collagen-related triple helices. Methods are also disclosed for making the novel collagen mimics.
Type:
Grant
Filed:
June 21, 2019
Date of Patent:
July 19, 2022
Assignee:
WISCONSIN ALUMNI RESEARCH FOUNDATION
Inventors:
Ronald T. Raines, Matthew D. Shoulders, Jonathan A. Hodges
Abstract: The invention concerns an improved process for the preparation of the dodecapeptide NX210 of SEQ ID NO: 1 in which the formation of side products is minimized.
Type:
Grant
Filed:
February 9, 2018
Date of Patent:
July 5, 2022
Assignee:
AXOLTIS PHARMA
Inventors:
Stéphane Gobron, Dominique Bridon, Frédéric Cabart, Christian Fauster
Abstract: The present invention provides a peptide of formula (I) or a pharmaceutical salt thereof wherein “m”, “n”, “p”, and “q” represent integers and are selected from 0 and 1; and “r” is comprised from 1 to 10; a linker birradical of formula (II), which is connecting an alpha carbon atom of an amino acid located at position “i” in the peptide sequence of formula (I) with an alpha carbon atom of an amino acid located at position “i+4” or “i+7” in the peptide sequence of formula (I); a C-terminal end corresponding to —C(O)R4; and a N-terminal end corresponding to —NHR5. Alternatively, the present invention provides a peptide or a pharmaceutical salt thereof which has an amino acid sequence with an identity from 85% to 95% with respect to sequence SEQ ID NO: 9: The peptides of the invention show anticancer activity.
Abstract: This disclosure describes three novel bisthioether stapled peptides as allosteric inhibitors of Polycomb Repressive Complex 2 (PRC2) catalytic function with demonstrated cell permeability, potent activity in physiological conditions, and strong antiproliferative effects on cancer cells. These inhibitors target, for the first time, two protein interfaces in PRC2 that are crucial for its proper assembling and thus for its histone methyltransferase activity.
Type:
Grant
Filed:
September 16, 2020
Date of Patent:
May 31, 2022
Assignee:
Research Foundation of the City University of New York
Inventors:
Guillermo Gerona-Navarro, Gan Zhang, Flavia Barragan
Abstract: The present invention relates to novel fragments of AIMP1 protein and a composition for improving alopecia and promoting hair growth comprising the same, more specifically it relates to a polypeptide consisting of 4 to 21 consecutive amino acids from the amino acid sequence of SEQ ID NO: 1, wherein the polypeptide comprises the 28th to 31st amino acid residue (KEKA) of amino acid sequence of SEQ ID NO: 1, or a polypeptide consisting of an amino acid sequence having 70% or more sequence homology with the polypeptide; a polynucleotide encoding the polypeptide; a pharmaceutical, cosmetic and food composition for improving alopecia and promoting hair growth comprising the polypeptide.
Type:
Grant
Filed:
July 27, 2017
Date of Patent:
April 26, 2022
Assignee:
CUREBIO THERAPEUTICS
Inventors:
Sunghoon Kim, Min Chul Park, Younha Kim
Abstract: The present invention relates to peptides with vasodilatory and/or diuretic functions. In particular, the invention relates to modifying key amino acid residues in natriuretic peptides to achieve different functions and properties. Accordingly the invention also includes modified natriuretic peptides. The invention also relates to the use of these peptides for regulating blood pressure-volume and/or treating a heart condition.
Abstract: This invention relates to novel compositions comprising analogs of naturally occurring polypeptides, wherein the analog comprises an ?-amino acid and at least one ?-amino acid. Administration of the compositions may be used for effecting treatment or prevention of a plurality of disease states caused by dysfunctional biochemical or biological pathways. The compositions and methods of this invention are particularly useful to identify novel therapeutic modulators of in-vivo receptor activity with extended half-lives and relevant bioactivity as compared to the naturally translated polypeptides upon which the analogs are derived.
Type:
Grant
Filed:
December 9, 2019
Date of Patent:
March 22, 2022
Assignee:
LONGEVITY BIOTECH, INC.
Inventors:
Scott Shandler, Samuel H. Gellman, John M. Gledhill
Abstract: The present invention is directed to somatostatin receptor antagonist compounds having the structure of Formula I, compositions comprising the same, and methods of using such compounds and compositions. The compounds may be useful in the prevention or treatment of hypoglycemia.
Type:
Grant
Filed:
February 9, 2017
Date of Patent:
March 22, 2022
Assignee:
CDRD VENTURES INC.
Inventors:
Stephen Paul Arns, James Brian Jaquith, Davy Jérémy Baudelet, Eric Roy Simonson, Richard Tom Liggins, Nag Sharwan Kumar, Tom Han Hsiao Hsieh
Abstract: The present invention relates to compounds having activity at the human glucose-dependent insulinotropic polypeptide (GIP) receptor. The present invention also relates to compounds having an extended duration of action at the GIP receptor. Such compounds may be useful in the treatment of diabetes, including type 2 diabetes mellitus (“T2DM”). Also, the compounds may be useful in the treatment of obesity.
Type:
Grant
Filed:
July 29, 2020
Date of Patent:
February 22, 2022
Assignee:
Eli Lilly and Company
Inventors:
Jorge Alsina-Fernandez, Andrea Renee Geiser, Lili Guo, Samantha Grace Lyons Keyser, John Lee, Hongchang Qu, William Christopher Roell
Abstract: Herein is reported a method for the production of a polypeptide that is biologically active as n-mer comprising a nucleic acid encoding a fusion polypeptide according to the following formula (Bn-CSo-Is-CSp-FC-CSq-It-CSr-Bm)u, wherein B denotes a polypeptide that is biologically active as n-mer and forms non-defined aggregates/multimers upon expression in the absence of a fused Fc-region, FC denotes a heavy chain Fc-region polypeptide, CS denotes a cleavage site, and I denotes an intervening amino acid sequence, wherein FC does not substantially bind to an Fc-receptor, recovering the fusion polypeptide from the cell or the cultivation medium, optionally cleaving the fusion polypeptide with a protease, and thereby producing a polypeptide that is biologically active as n-mer and forms non-defined aggregates/multimers upon expression in the absence of a fused Fc-region.
Type:
Grant
Filed:
January 30, 2020
Date of Patent:
February 22, 2022
Assignee:
Hoffmann-La Roche Inc.
Inventors:
Johannes Auer, Martin Bader, Stefan Dengl, Stefan Lorenz, Stefan Seeber
Abstract: The present invention relates to micelle drug carriers and methods of using the micelles to deliver drugs to target cells. The micelles are useful, for example, for carrying and targeting drugs for the treatment of cancer to cancer cells. As one example, the disclosure provides pegylated octadecyl lithocholate micelles that are labeled with a peptide ligand for colorectal neo-plasia and that carry the small molecule mTOR inhibitor rapamycin to colorectal cancer cells.
Type:
Grant
Filed:
December 1, 2016
Date of Patent:
February 1, 2022
Assignee:
THE REGENTS OF THE UNIVERSITY OF MICHIGAN
Abstract: The present invention provides cystobactamides of formula (I): R1—Ar1-L1-Ar2-L2-Ar3-L3-Ar4-L4-Ar5—R2 and the use thereof for the treatment or prophylaxis of bacterial infections.
Type:
Grant
Filed:
June 10, 2020
Date of Patent:
January 18, 2022
Assignee:
HELMHOLTZ-ZENTRUM FÜR INFEKTIONSFORSCHUNG GMBH
Inventors:
Sascha Baumann, Jennifer Herrmann, Kathrin Mohr, Heinrich Steinmetz, Klaus Gerth, Ritesh Raju, Rolf Müller, Rolf W. Hartmann, Mostafa Hamed, Walid A. M. Elgaher, Maria Moreno, Franziska Gille, Liang Liang Wang, Andreas Kirschning, Stephan Huettel
Abstract: This disclosure concerns a method for making a hybrid organic/inorganic material having an architecture. The method includes combining a peptoid comprising a sequence of N-substituted glycine residues and an inorganic material or inorganic material precursor to form a hybrid organic/inorganic material comprising the peptoid and the inorganic material, the hybrid organic/inorganic material having an architecture based at least in part on the peptoid sequence. The hybrid organic/inorganic materials include a cluster of nanoparticles of an inorganic material and peptoids, the cluster formed by random attachment of nanoparticles to one another by peptoid-peptoid and peptoid-nanoparticle surface interactions, wherein the hybrid material has an architecture based at least in part on the peptoid sequence.
Abstract: The present invention relates to the field of antimicrobial enzymes. In particular, the present invention relates to a polypeptide comprising an amino acid sequence exhibiting at least 90% sequence identity with the sequence of SEQ ID NO:1, with the proviso that the polypeptide does neither comprise the sequence according to SEQ ID NO:2, nor the sequence according to SEQ ID NO:3, nor the sequence according to SEQ ID NO:4. The present invention relates also to nucleic acids encoding an inventive polypeptide, vectors or bacteriophages comprising an inventive nucleic acid as well as host cells comprising an inventive polypeptide, nucleic acid, vector, and/or bacteriophage. Similarly, the present invention relates to compositions comprising a polypeptide, nucleic acid, vector, bacteriophage, and/or host cell according to the present invention.
Abstract: The present invention relates to cyclic peptide compounds which inhibit or antagonize the binding of methylglyoxal (MG) and/or other reactive carbonyl species (RCS) to an arginine- or lysine-containing protein. Preferred scavenger compounds are said cyclic peptides comprising a specific amino acid motif and a hydrophobic modification, and pharmaceutical compositions thereof. The present invention furthermore relates to the use of the cyclic peptides as scavenger or antagonists of methylglyoxal and/or related reactive carbonyl species (RCS). The present invention furthermore relates to the use of the cyclic peptides for the prevention and/or treatment of a disease caused by or associated with methylglyoxal (MG) and/or reactive carbonyl species (RCS), in particular caused by or associated with elevated MG levels, such as diabetes and its associated complications, cardiovascular diseases and obesity.
Type:
Grant
Filed:
November 6, 2017
Date of Patent:
December 21, 2021
Assignee:
RUPRECHT-KARLS-UNIVERSITÄT HEIDELBERG
Inventors:
Sebastian Brings, Thomas H. Fleming, Walter Mier, Peter P. Nawroth
Abstract: The invention is directed to a composition comprising a fibrin hydrogel conjugated to peptides of laminin-111 (L1) and methods for repairing damaged salivary tissue using the composition.
Type:
Grant
Filed:
September 19, 2017
Date of Patent:
December 7, 2021
Assignees:
UNIVERSITY OF UTAH RESEARCH FOUNDATION, UNIVERSITY AT BUFFALO
Inventors:
Olga Baker, Kihoon Nam, Pedro Lei, Stelios Andreadis
Abstract: Disclosed are an exenatide modifier for connecting the exenatide to a fatty chain with a carboxy in the terminus thereof by means of a hydrophilic connecting arm, and a use thereof in preparing drugs serving as a GLP-1 receptor agonist; a use in preparing drugs for preventing and/or treating diseases and/or symptoms associated with a low GLP-1 receptor activity; a use in preparing drugs for diseases and/or symptoms associated with glycometabolism; a use in preparing drugs for diabetes; a use in preparing drugs for fatty liver disease, and a use in preparing drugs for losing weight.